

ASX ANNOUNCEMENT

MANUFACTURING PARTNER APPOINTED BY CELLMID

- **Rodon Biologics will be Cellmid's manufacturing partner of its CAB102 antibody**
- **Rodon has already completed manufacturability studies of the drug for the clinic**
- **Partnership is expected to save six months in 'time to clinic' for CAB102**
- **Clinical program on track for first in human studies in early 2015**

SYDNEY, Thursday, 19 June 2014: Cellmid Limited (ASX:CDY) is pleased to advise that it has selected Rodon Biologics, a subsidiary of Biotechnol SA, to manufacture its humanised anti-midkine (MK) antibody CAB102 for clinical trials in multiple oncology indications. Under the agreement, Rodon will engineer a high yielding CHO cell line expressing CAB102, along with the processes necessary to manufacture and formulate the drug for first in human trials.

CAB102 is Cellmid's lead oncology drug following antibody humanisation and pre-clinical testing (see ASX announcement 7 May 2014). Biotechnol Ltd, the biopharmaceutical development subsidiary of Biotechnol SA, has been responsible for the humanisation of the antibody. Rodon produced the humanised candidates for initial screening and has already tested CAB102's manufacturability and stability in small-scale production runs as part of the humanisation program. In addition, and following a successful humanisation project, Cellmid and Biotechnol Ltd have recently entered into a co-development agreement to engineer novel anti-cancer Tribodies™ (see ASX announcement 15 April 2014).

"Contracting Rodon Biologics to manufacture CAB102 makes sense for many reasons", said Cellmid's CEO, Maria Halasz. "Cellmid and Rodon/Biotechnol have collaborated closely during the humanisation of CAB102 establishing a very productive working relationship. Also critical in our decision was their deep understanding of the specific manufacturing requirements for our planned CTN (Clinical Trial Notification) scheme based clinical studies," she added.

This manufacturing collaboration will be the third project between the parties and aligns well with the ongoing anti-MK Tribody program. It allows for seamless transition by Rodon from manufacturability studies to actual cell line development and manufacture, which is expected to save up to six months in the Company's product development program.

Rodon/Biotechnol was one of the early biologics manufacturers in Europe with a 14-year record of accomplishment and with many successful projects at various stages of the drug development spectrum. With the appointment of Rodon Biologics Cellmid's clinical program for CAB102 is progressing as planned with first-in-human studies expected to commence in early 2015.

End

Contact: Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in immuno-oncology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information, please see www.cellmid.com.au.

Biotechnol Ltd

Biotechnol Ltd is a clinical stage biopharmaceutical company based in the UK with a strong track record in antibody drug development. The company has a proprietary Tribody™ platform for the engaging of various immunological effector functions including T-cells and NK-cells. The Company is looking to strengthen this solid asset base by developing candidates with a dual approach involving novel targets and checkpoint regulators. For further information, please see www.biotechnol.com.

Rodon Biologics

Rodon Biologics is a fully owned subsidiary of Biotechnol SA based in Lisbon, Portugal. The company has been providing excellence in development of biopharmaceutical products for over 14 years and has successfully completed numerous product and process development projects for different stages in the drug development cycle. Rodon manufactured biologics range from research to clinical trial Phase III stages. The Company has broad experience working with biotechnology and pharmaceutical companies of various sizes and locations. Products developed include cytokines, growth factors, antibody fragments, immunotoxins, antibodies and multi-specific antibody based formats.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as part of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only present in a disease context, and targeting midkine is not expected to harm normal healthy tissues.